Suming Wang

Suming Wang is currently serving as the Director of Translational Medicine in the Medical Science - Early department at Mitsubishi Tanabe Pharma America since October 2024. Prior to this, Suming Wang held various roles at Vigeo Therapeutics from September 2016 to October 2024, including Head of CLIA Lab & Translational Science and Principal Scientist, where responsibilities included overseeing the CLIA clinical laboratory, collaborating with the FDA for biomarker assay approvals, and managing translational and preclinical programs in oncology and autoimmune diseases. Earlier experience includes a research fellowship at Boston Children's Hospital focused on cancer research, and a research associate position at the University of Wisconsin-Madison concentrating on assay development. Suming Wang obtained a Ph.D. in Biochemistry and Molecular Biology and a Bachelor's degree in Life Science from the University of Science and Technology of China.